Popular weight loss drugs, painkillers, and other common medications are seeing their list prices go up this month.
Some adverse event reports link alopecia and suicide ideation to GLP-1 drug use, but the FDA says the reports do not prove causation.
Semaglutide and other new drugs are the real deal in obesity treatment, but there are many lingering questions about their future.
There have been nearly 3,000 calls to poison control centers linked to the weight loss drug semaglutide, officials said.
People who stopped taking Zepbound (tirzepatide) regained much of their lost weight within a year, while those on it kept losing more.
People with alcohol use disorder who took semaglutide, also known as Wegovy, drank less and had fewer cravings for alcohol, new research found.
In clinical trials, Eli Lilly's tirzepatide was found to help people lose upwards of 20% of their weight in conjunction with diet and exercise.
People who already lost weight at first went on to shed substantially more pounds than those on a placebo, Eli Lilly's newest clinical trial found.
The active ingredient in Mounjaro, tirzepatide, is expected to soon be the next major obesity treatment but is already being sold through sketchy sources.
According to Novo Nordisk, people on Wegovy were 20% less likely to develop serious cardiovascular problems for up to five years when compared to placebo.
A Louisiana woman claims that she has suffered severe vomiting, stomach pain, and teeth loss as a result of taking the popular weight loss drugs.
Weight loss drugs including Ozempic and Saxenda are under review after patients reported depressive side effects.
The FDA has received adverse event reports from people using compounded semaglutide, which might not contain the same version of the popular obesity drug.
People given oral semaglutide lost about 15% of their weight over 68 weeks, according to the company.
Eli Lilly recently dropped the copay price of the diabetes drug Humalog to $35 a month, but it’s not the only company with inflated insulin prices.
Celebrities and other influencers on social media, including Elon Musk, have posted about using the drug.
The American Academy of Pediatrics' guidelines are the first to emphasize proactive measures for treating childhood obesity, which has risen in recent years.
The next generation of obesity treatments, a controversial Alzheimer's drug, and male birth control are all coming in 2023.
Children 12 and older lost an average 14.7% of their initial body weight over a year’s time while taking Wegovy.
Cancer-fighting viruses, gene therapies, and a new class of hair loss drugs are some of the year's most exciting medical advances.
